Biggest Decliners on the ASE YTD 2025

June 08, 2025

Biggest Decliners

The biggest decliners on this list have had the greatest percentage decrease in share price year to date. This means each stock has seen its share price decline at a faster rate than the rest of the market so far this year. Companies that are experiencing dramatic decreases in share price can do so for a variety of reasons, including the sector they are in has turned (such as companies in an unfavorable commodities space or a sector that has been disrupted), or the company is experiencing financial difficulties generally due to an inability to service its debt.

American Stock Exchange

NYSE American, formerly known as the American Stock Exchange (ASE), and more recently as NYSE MKT, is an American stock exchange located in New York City.

About the Data

This table includes the top companies based on their percentage decrease in share price year to date.

How do you use this table?

The biggest decliners are companies with downward momentum and potentially higher reward as a short position. These stocks tend to have a higher trading volume and visibility in the marketplace. Stocks in this group can change direction quickly and tend to be short term trades. Stocks in this category are generally sold to preserve capital or held for speculation or a short position.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameTotal ReturnPeriod
AEON AEON Biopharma Inc -98.52 YTD
ATCH AtlasClear Holdings Inc -97.92 YTD
KNW Know Labs Inc -92.81 YTD
FOXO FOXO Technologies Inc -86.24 YTD
CVM CEL-SCI Corp -82.50 YTD
GRO Brazil Potash Corp -78.57 YTD
UAVS AgEagle Aerial Systems Inc -77.23 YTD
TOVX Theriva Biologics Inc -73.32 YTD
UMAC Unusual Machines Inc -70.51 YTD
CLDI Calidi Biotherapeutics Inc -69.54 YTD
All data provided as at market close May 29, 2025.

Company Details

AEON Biopharma Inc

AEON:ASE

Total Return

-98.52

Period

YTD

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Access the stockcalc valuation


AtlasClear Holdings Inc

ATCH:ASE

Total Return

-97.92

Period

YTD

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading.

Access the stockcalc valuation


Know Labs Inc

KNW:ASE

Total Return

-92.81

Period

YTD

Know Labs Inc is a medical diagnostic. The company is focused on the development, marketing, and sales of proprietary technologies that are capable of uniquely identifying or authenticating almost any substance or material using electromagnetic energy to record, detect, and identify the signature of the substance or material known as Bio-RFID and ChromaID technologies. It is developing a wearable device that will measure blood glucose without fingersticks or microneedles.

Access the stockcalc valuation


FOXO Technologies Inc

FOXO:ASE

Total Return

-86.24

Period

YTD

FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. The company's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life. The Company manages and classifies its business into two reportable business segments: Healthcare; and Labs and Life.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

CEL-SCI Corp

CVM:ASE

Total Return

-82.50

Period

YTD

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances.

Access the stockcalc valuation


Brazil Potash Corp

GRO:ASE

Total Return

-78.57

Period

YTD

Brazil Potash Corp is a mineral exploration and development company with a potash mining project located in the state of Amazonas, Brazil. The company's technical operations are based in Autazes, Amazonas, Brazil, and Belo Horizonte, Minas Gerais, Brazil. The operating activities of the company include focusing on the extraction and processing of potash ore from the underground mine of the Autazes Project and selling and distributing the processed potash in Brazil.

Access the stockcalc valuation


AgEagle Aerial Systems Inc

UAVS:ASE

Total Return

-77.23

Period

YTD

AgEagle Aerial Systems Inc is actively engaged in designing and delivering drones, sensors and software that solve important problems for its customers. It designs, produces, distributes, and supports technologically advanced small unmanned aerial systems (UAVs) that it offers for sale commercially to the precision agriculture industry. Its segments include Drones, Sensors and Software-as-a-Service (SaaS). The company's majority revenue is derived primarily through sensors.

Access the stockcalc valuation


Theriva Biologics Inc

TOVX:ASE

Total Return

-73.32

Period

YTD

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Access the stockcalc valuation


Unusual Machines Inc

UMAC:ASE

Total Return

-70.51

Period

YTD

Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.

Access the stockcalc valuation


Calidi Biotherapeutics Inc

CLDI:ASE

Total Return

-69.54

Period

YTD

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
AEON Biopharma and AtlasClear Holdings were the biggest decliners on the ASE YTD. See all the biggest decliners on the blog: https://www.stockcalc.com/Blog/biggest-decliners-ase-ytd-2025
AEON Biopharma $AEON and AtlasClear Holdings $ATCH were the biggest decliners on the #ASE YTD. See the full list of decliners: https://www.stockcalc.com/Blog/biggest-decliners-ase-ytd-2025
AEON Biopharma and AtlasClear Holdings were the biggest decliners on the ASE YTD. See all the biggest decliners on the blog: https://www.stockcalc.com/Blog/biggest-decliners-ase-ytd-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.